Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults

被引:31
作者
Hedlund, J [1 ]
Strålin, K
Örtqvist, Å
Holmberg, H
机构
[1] Karolinska Univ Hosp, Dept Infect Dis, S-17176 Stockholm, Sweden
[2] Orebro Univ Hosp, Dept Infect Dis, Orebro, Sweden
[3] Karolinska Univ Hosp, Dept Communicable Dis Control & Prevent, S-17176 Stockholm, Sweden
关键词
D O I
10.1080/00365540500264050
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This document presents the evidence-based guidelines of the Swedish Society of Infectious Diseases for the management of adult immunocompetent patients with community-acquired pneumonia ( CAP), who are assessed at hospital. The prognostic score 'CURB-65' is recommended for all CAP patients in the emergency room. The score provides an assessment tool for the decision regarding outpatient treatment or level of hospital supervision, the choice of microbiological investigations, and empirical antibiotic treatment. In patients with non-severe CAP (CURB-65 score 0-2) we recommend initial narrow-spectrum antibiotic treatment, orally or intravenously, primarily directed at Streptococcus pneumoniae. In those with CURB-65 score 3, penicillin G or a cephalosporin intravenously is recommended. For CURB-65 score 0-3 atypical pathogens should be covered only when they are suspected on clinical or epidemiological grounds. In patients with CURB-65 score 4-5 intravenous combination therapy with either cephalosporin/macrolide or penicillin G/fluoroquinolone is recommended. Efforts should be made to identify the CAP aetiology in order to support the ongoing antibiotic treatment or to suggest treatment alterations. Recommended measures for prevention of CAP include influenza - and pneumococcal - vaccination to risk groups and efforts for smoking cessation.
引用
收藏
页码:791 / 805
页数:15
相关论文
共 173 条
[1]  
ANDREWS BE, 1987, Q J MED, V62, P195
[2]   Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia [J].
Baddour, LM ;
Yu, VL ;
Klugman, KP ;
Feldman, C ;
Ortqvist, A ;
Rello, J ;
Morris, AJ ;
Luna, CM ;
Snydman, DR ;
Ko, WC ;
Chedid, MBF ;
Hui, DS ;
Andremont, A ;
Chiou, CCC .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 170 (04) :440-444
[3]  
BARTLETT JG, 1978, AM REV RESPIR DIS, V117, P1019
[4]  
Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954
[5]  
Bernander Sverker, 1997, Clin Microbiol Infect, V3, P95
[6]   ETIOLOGY OF COMMUNITY-ACQUIRED PNEUMONIA IN PATIENTS REQUIRING HOSPITALIZATION [J].
BERNTSSON, E ;
BLOMBERG, J ;
LAGERGARD, T ;
TROLLFORS, B .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1985, 4 (03) :268-272
[7]   Protection against influenza after annually repeated vaccination -: A meta-analysis of serologic and field studies [J].
Beyer, WEP ;
de Bruijn, IA ;
Palache, AM ;
Westendorp, RGJ ;
Osterhaus, ADME .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (02) :182-188
[8]   Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy A meta-analysis [J].
Beyer, WEP ;
Palache, AM ;
de Jong, JC ;
Osterhaus, ADME .
VACCINE, 2002, 20 (9-10) :1340-1353
[9]   Bottle-blowing in hospital-treated patients with community-acquired pneumonia [J].
Bjorkqvist, M ;
Wiberg, B ;
Bodin, L ;
Barany, M ;
Holmberg, H .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1997, 29 (01) :77-82
[10]   Early recognition of Streptococcus pneumoniae in patients with community-acquired pneumonia [J].
Bohte, R ;
Hermans, J ;
vandenBroek, PJ .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1996, 15 (03) :201-205